As for the immunosuppressive effects of melanoma, CTLA4 was significantly increased in the tumor in patients with metastatic melanoma, consistent with the current efficacy of clinical application of the anti-CTLA4 antibody for advanced melanoma [14]. The gene discussed is CTLA4; the disease is neoplasm.